Secukinumab effective in moderate-to-severe psoriasis

Secukinumab effective in moderate-to-severe psoriasis
For patients with moderate-to-severe plaque psoriasis, the fully human anti-interleukin-17A monoclonal antibody, secukinumab, is effective, according to research published online July 9 in the New England Journal of Medicine.

(HealthDay)—For patients with moderate-to-severe plaque psoriasis, the fully human anti-interleukin-17A monoclonal antibody, secukinumab, is effective, according to research published online July 9 in the New England Journal of Medicine.

Richard G. Langley, M.D., from Dalhousie University in Halifax, Canada, and colleagues assessed secukinumab in two phase 3 trials involving patients with moderate-to-severe plaque psoriasis. The Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis (ERASURE) trial involved 738 patients and the Full Year Investigative Examination of Secukinumab versus Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis (FIXTURE) study involved 1,306 patients. Patients were randomized to 300 mg or 150 mg subcutaneous secukinumab or placebo, or to etanercept in the FIXTURE study.

The researchers found that in both studies the proportion of patients who had a reduction of 75 percent or more from baseline in the psoriasis area-and-severity index score was higher with each secukinumab dose versus placebo or etanercept. The rates were 81.6 and 71.6 percent, respectively, with 300 and 150 mg of secukinumab, compared to 4.5 percent with placebo in the ERASURE study. In the FIXTURE study, the rates were 77.1 and 67.0 percent, respectively, with 300 and 150 mg of secukinumab, compared to 44.0 percent with and 4.9 percent with (P < 0.001 for secukinumab doses versus comparators).

"Secukinumab was effective for in two randomized trials, validating interleukin-17A as a therapeutic target," the authors write.

The study was funded by Novartis, the manufacturer of secukinumab.

More information: Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Etanercept cuts sciatic pain from lumbar disc herniation

Nov 01, 2013

(HealthDay)—Compared with placebo, transforaminal injections of etanercept provide relief from leg and back pain in patients with symptomatic lumbar disc herniation (LDH), according to research published ...

Many psoriasis patients undertreated for CV risk factors

Jun 22, 2012

(HealthDay) -- A large proportion of patients with moderate-to-severe plaque psoriasis are underdiagnosed and undertreated for cardiovascular (CV) risk factors, according to a study published in the July issue ...

Study compares effectiveness of psoriasis treatments

Apr 20, 2012

(HealthDay) -- The effectiveness of therapies for psoriasis is variable, and may be lower in real-world settings than in trial settings, according to a study published in the April issue of the Archives of ...

Recommended for you

Boost in quest for TB breath test

1 hour ago

A simple breath test may one day show whether someone has a strain of tuberculosis that will respond to a frontline antibiotic, or a drug-resistant type, scientists said Tuesday.

Three more dead from Legionnaire's disease in Spain

1 hour ago

Three more people have died from Legionnaire's disease in Catalonia in northeastern Spain, officials said Tuesday, bringing to seven the death toll from the lung infection in the region in just over a week.

User comments